Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Burrill & Co. Launches Fourth Fund With $313 Million And Aims For More

This article was originally published in The Pink Sheet Daily

Executive Summary

Fresh from an exceptional return on its investment in recently-acquired Pharmasset, the San Francisco firm already has enough to make Burrill Capital Fund IV its largest fund yet.


Related Content

Rusnano’s Grand Ambitions In Biotech
Gilead Goes For The Gold (Standard) In Plan To Acquire HCV Specialist Pharmasset
To Russia, With Love: Selecta, BIND To Create Subsidiaries In Financing Deals With Rusnano
Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market
Health Care Information Technology: Venture's New Darling?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts